Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study

Published:2024-12 Issue: Volume:36 Page:102152
ISSN:2451-9936
Container-title:American Journal of Ophthalmology Case Reports
language:en
Short-container-title:American Journal of Ophthalmology Case Reports

Author:

Chakraborty Debdulal^ORCID,Sharma Ashish,Mondal Soumen,Sheth Jay,Sinha Tushar Kanti,Boral Subhendu,Mukherjee Angshuman,Bhattacharya Ranabir,Maitra Ritobroto

Publisher

Elsevier BV

Reference20 articles.

1. Diabetic retinopathy;Wong;Nat Rev Dis Prim,2016

2. IDF Diabetes Atlas: global, regional, and country-level diabetes prevalence estimates for 2021 and projections for 2045;Sun;Diabetes Res Clin Pract,2022

3. Diabetic retinopathy and VEGF;Gupta;Open Ophthalmol J,2013

4. Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: a real-world case series;Chakraborty;Am J Ophthalmol Case Rep,2021

5. Faricimab for treatment-resistant diabetic macular edema;Rush;Clin Ophthalmol,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP